12 Month Price Forecast For LXRX
Distance to LXRX Price Forecasts
LXRX Price Momentum
🤔 Considering Lexicon (LXRX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 9:57 AM UTC
LXRX Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, LXRX has a consensus that is bullish. The median price target is $2.00, with forecasts ranging from $0.80 to $10.00. Currently, there are 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With LXRX currently trading at $0.84, the median price forecast suggests a 138.1% upside. The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 1,090.5% upside, while at provides the most conservative target, suggesting a -4.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LXRX Analyst Consensus
LXRX Price Target Range
Latest LXRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LXRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 23, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 25, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 22, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 13, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $6.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $6.00 |
| Nov 1, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $6.00 |
| Oct 30, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Sep 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Sep 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Aug 2, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $10.00 |
Stocks Similar to Lexicon Pharmaceuticals Inc
The following stocks are similar to Lexicon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lexicon Pharmaceuticals Inc (LXRX) Financial Data
Lexicon Pharmaceuticals Inc has a market capitalization of $284.96M with a P/E ratio of -1.1x. The company generates $5.23M in trailing twelve-month revenue with a 92.9% profit margin.
Revenue growth is +980.2% quarter-over-quarter, while maintaining an operating margin of -3,639.6% and return on equity of -136.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Lexicon Pharmaceuticals Inc (LXRX) Company Overview
About Lexicon Pharmaceuticals Inc
Develops innovative pharmaceutical products.
Lexicon Pharmaceuticals operates by discovering, developing, and commercializing small molecule drug candidates. The company generates revenue through strategic collaborations and licensing agreements with major pharmaceutical companies, which support its ongoing clinical trials and drug development efforts.
Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon is advancing several drug candidates, including Sotagliflozin, LX9211, and LX2761, targeting various medical conditions such as heart failure, type 1 diabetes, and neuropathic pain. The company's partnerships with established firms like Bristol-Myers Squibb and Genentech enhance its market potential and resource access.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
285
CEO
Dr. Michael Exton Ph.D.
Country
United States
IPO Year
2000
Website
www.lexpharma.comLexicon Pharmaceuticals Inc (LXRX) Latest News & Analysis
Lexicon Pharmaceuticals will host an event discussing LX9211, its investigational non-opioid treatment for DPNP, featuring expert insights and a Q&A session.
Lexicon's LX9211 represents potential market disruption in pain management, impacting revenue forecasts and attracting investor interest in innovative therapies.
Lexicon Pharmaceuticals, Inc. has appointed Scott Coiante as senior vice president and chief financial officer, effective January 2, 2025.
The appointment of a new CFO can signal potential shifts in financial strategy and performance, impacting investor confidence and stock price for Lexicon Pharmaceuticals.
The FDA has rejected Lexicon Pharmaceuticals' add-on drug intended for type 1 diabetes and chronic kidney disease, impacting the company's product pipeline.
The FDA's rejection of Lexicon Pharmaceuticals' drug could negatively impact the company's stock price and future revenue potential, signaling challenges in drug development.
Lexicon Pharmaceuticals received a complete response letter from the FDA for Zynquista (sotagliflozin), halting its launch plans and shifting focus to its clinical development pipeline.
The CRL from the FDA may delay Zynquista's market entry, potentially impacting Lexicon's revenue projections and stock performance, as the company shifts focus to its development pipeline.
Trial enrollment exceeded targets by 20% and was completed ahead of schedule, indicating strong interest in participation.
Exceeding enrollment targets suggests strong market demand and potential for successful trial outcomes, which can positively impact stock performance and investor confidence.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at two investor conferences in December, featuring CEO Mike Exton among the speakers.
Lexicon Pharmaceuticals' upcoming presentations may signal strategic updates or developments, potentially affecting stock performance and investor sentiment.
Frequently Asked Questions About LXRX Stock
What is Lexicon Pharmaceuticals Inc's (LXRX) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Lexicon Pharmaceuticals Inc (LXRX) has a median price target of $2.00. The highest price target is $10.00 and the lowest is $0.80.
Is LXRX stock a good investment in 2025?
According to current analyst ratings, LXRX has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LXRX stock?
Wall Street analysts predict LXRX stock could reach $2.00 in the next 12 months. This represents a 138.1% increase from the current price of $0.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexicon Pharmaceuticals Inc's business model?
Lexicon Pharmaceuticals operates by discovering, developing, and commercializing small molecule drug candidates. The company generates revenue through strategic collaborations and licensing agreements with major pharmaceutical companies, which support its ongoing clinical trials and drug development efforts.
What is the highest forecasted price for LXRX Lexicon Pharmaceuticals Inc?
The highest price target for LXRX is $10.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 1,090.5% increase from the current price of $0.84.
What is the lowest forecasted price for LXRX Lexicon Pharmaceuticals Inc?
The lowest price target for LXRX is $0.80 from at , which represents a -4.8% decrease from the current price of $0.84.
What is the overall LXRX consensus from analysts for Lexicon Pharmaceuticals Inc?
The overall analyst consensus for LXRX is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are LXRX stock price projections?
Stock price projections, including those for Lexicon Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
